- Conditions
- Postmenopause
- Interventions
- Bazedoxifene 10 mg/CE 0.625 mg, Bazedoxifene 20 mg/CE 0.625 mg, Bazedoxifene 40 mg/CE 0.625 mg, Bazedoxifene 10 mg/CE 0.45 mg, Bazedoxifene 20 mg/CE 0.45 mg, Bazedoxifene 40 mg/CE 0.45 mg, Raloxifene 60 mg, Placebo
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 40 Years to 75 Years · Female only
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 22
- States / cities
- Fort Myers, Florida • Gainesville, Florida • New Port Richey, Florida + 19 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–1
of 1
matching trial from the live ClinicalTrials.gov search.